ABSTRACT: Learning and memory deficits in Alzheimer's disease (AD) result from synaptic failure and neuronal loss, the latter caused in part by excitotoxicity and oxidative stress. A therapeutic approach is described that uses NO-chimeras directed at restoration of both synaptic function and neuroprotection. 4-Methylthiazole (MZ) derivatives were synthesized, based upon a lead neuroprotective pharmacophore acting in part by GABA A receptor potentiation. MZ derivatives were assayed for protection of primary neurons against oxygen−glucose deprivation and excitotoxicity. Selected neuroprotective derivatives were incorporated into NO-chimera prodrugs, coined nomethiazoles. To provide proof of concept for the nomethiazole drug class, selected examples were assayed for restoration of synaptic function in hippocampal slices from AD-transgenic mice, reversal of cognitive deficits, and brain bioavailability of the prodrug and its neuroprotective MZ metabolite. Taken together, the assay data suggest that these chimeric nomethiazoles may be of use in treatment of multiple components of neurodegenerative disorders, such as AD.
■ INTRODUCTION
Alzheimer's disease (AD) is an age-related neurodegenerative disease manifested by progressive memory loss, decline in language skills, and other cognitive impairments. The disorder is reaching epidemic proportions, with a large human, social, and economic burden. 1 Currently approved treatments may temporarily reduce the rate of cognitive decline in a limited number of patients, without halting disease progression; however, no treatment is considered disease-modifying. 2 Diverse factors play a role in the pathogenesis of AD, notably abnormal aggregation of amyloid β (Aβ) and tau protein, glutamate-induced excitotoxicity, oxidative stress, and inflammation. 3 Accordingly, a variety of therapeutic strategies modulating the progression or prevention of AD are currently being investigated. 4 ,5 AD represents a major unmet medical need.
Excitotoxicity is a mechanism of neuronal dysfunction and cell death characterized by excessive stimulation of glutamate receptors, pathological elevation of intracellular calcium concentration, and mitochondrial damage. The methylthiazole (MZ) containing GABA-mimetic agent clomethiazole (CMZ, Scheme 1) potentiates the function of the inhibitory neurotransmitter GABA in the brain, 6 −8 attenuating glutamate induced excitotoxicity. CMZ has seen clinical use in a number of indications, 9−11 and study of compounds related to CMZ has shown that anticonvulsant and hypnotic potency could be dissociated and modulated separately. 12−17 Under the name Zendra, CMZ was explored in clinical trials including phase III trials as a neuroprotective drug for use in spinal cord injury and ischemic stroke, 18−25 and CMZ continues to be suggested as a potential component of future combination therapies for neuronal injury. 26 CMZ has also been demonstrated to counteract inflammation, lowering levels of proinflammatory cytokines, including TNFα, 27, 28 and to rescue mitochondrial function in brain tissues. 29 Recent evidence, from both clinical observations and mouse model studies, supports TNFα as a therapeutic target in AD. 30−32 Likewise, restoration of mictochondrial function is seen as a strategy for AD therapy. 33, 34 Therefore, MZ derivatives, capable of eliciting neuroprotection and attenuating neuroinflammation, are of potential clinical utility in AD.
An early event in AD is synaptic failure. 35 Restoration of synaptic function via activation of cAMP-responsive element binding factor (CREB) is seen as a new target for treatment of AD and other neurological disorders. 36−43 Activation of CREB is known to enhance or restore long-term potentiation (LTP) and the expression of corresponding gene products to enhance neuronal plasticity and neurogenesis. 44−46 Since activation of CREB in the hippocampus is tightly coupled to NO/cGMP signaling, 44 ,46−49 restoration of normal NO/cGMP signaling in the aging brain is essential to preserve both synaptic and neuronal survival and function. NO-mimetic agents that enhance CREB activity will likely be of benefit in treatment of AD. 50 We have previously reported a chimeric molecule with NO and GABA-mimetic attributes, 1 (GT-1061), that contains an MZ pharmacophore (Scheme 1). 50 1 significantly improved learning and memory in rats with cognitive deficits in the cholinergic systems of the basal forebrain. 37 A key objective of the present study was to determine if 1 is a prototype of an NO-chimera drug class. A positive observation would allow further optimization and refinement of this drug class for AD and other CNS indications. We report herein (1) the development of a small MZ library, (2) selection of MZ derivatives based upon neuroprotective activity screened in primary neurons, (3) synthesis of novel NO-chimeras, coined nomethiazoles, (4) selection based upon chemical stability, (5) assay for synaptic rescue in brain slices, (6) assay for restoration Scheme 2 a of learning and memory in vivo, and (7) demonstration of brain bioavailability and measurement of brain/plasma ratios. The drug design approach is depicted in Scheme 1.
■ RESULTS AND DISCUSSION 1. Synthesis of MZ Derivatives. Copper(I)-catalyzed Huisgen [3 + 2] -cycloaddition between an azide and a terminal alkyne was used to afford regioselectively 1,4-disubstituted-1H-1,2,3-triazoles, based upon the mild conditions, reliable high yield, and chemoselectivity of this "click" reaction. 51−53 Azide 3 was synthesized in two steps and reacted with commercially available alkynes, including alkyl (e.g., 1-hexyne, ethynyltrimethylsilane, propargylbenzene) and aryl (e.g., ethynylbenzene, regioisomers of ethynylpyridine, 3-ethynylthiophene, and 5-ethynyl-1-methyl-1H-imidazole), to generate a small library of 4-methyl-5-(phenyl(1H-1,2,3-triazol-1-yl)methyl)thiazole derivatives (5a−i), and in addition, one fluorinated analogue 8 was also prepared (Scheme 2). The goal was to increase diversity of MZ derivatives and identify novel neuroprotective scaffolds. Accordingly 5-(2-(1H-1,2,3-triazol-1-yl)ethyl)-4-methylthiazole derivatives (11a−c) and two 5-benzyl-4-methylthiazole derivatives were synthesized (6a,b). Of all the click products, compound 5d was identified as an excellent neuroprotectant using in vitro bioassays (discussed below), whereas removal of the 3-pyridyl substitutent (5i), replacement of the pyridine ring with phenyl (5b) or other heterocycles (5g, 5h), and changing the position of the nitrogen (5e, 5f) led to reduced efficacy. A similar structure−activity pattern was observed for 11a−c. Thus, the 3-(1H-1,2,3-triazole-4-yl)-pyridine fragment is a potential neuroprotective pharmacophore and was used to develop further MZ derivatives.
Synthesis of MZ analogues, retaining the 5-ethyl-4-methylthiazole motif of both CMZ and 1, proceeded from 4-methyl-5-vinylthiazole (19) to yield the alcohols 22 and 23 (Scheme 3). Epoxide intermediate 21 was added dropwise to Grignard reagents to give 22a−c as major products. Although the ultimate objective was to modify MZ derivatives as NOchimeras, compounds such as the indole derivative 24 served to extend and explore the MZ structural space. Compound 24 also represents an analogue of latrepirdine, a once-promising new AD drug. 54 Tetrahydrocarboline, the starting material for 24, was made according to a published procedure. 55 To incorporate the newly discovered 3-(1H-1,2,3-triazole-4-yl)pyridine pharmacophore into NO-chimera scaffolds, azido alcohol 25 was obtained by treating epoxide 21 with sodium azide and reacting with 3-ethylnylpyridine under standard click chemistry conditions to give cycloaddition product 26. Compound 31, a close structural analogue of 26, was synthesized from 22c using Suzuki coupling to investigate the tolerance of neuroprotection to triazole ring replacement in the novel pharmacophore.
2. CMZ Pharmacology Underlying the Design and Biossay of MZ Derivatives. Many papers have discussed the biological activity of CMZ in clinical settings and in animal models. Thiazole derivatives have long been known to manifest sedative/hypnotic and anticonvulsant effects that are indicative of GABA-mimetic activity. 15, 16 The prototype NO-chimera 1 releases 5-(2-hydroxyethyl)-4-methylthiazole (HMZ) as primary metabolite, which was first reported in 1956 to be an anticonvulsant agent in rabbits. 56 CMZ has been shown extensively to be neuroprotective in animal models of transient and global ischemia. CMZ potentiates GABA and muscimol agonism at the GABA A receptor without evidence for The mechanism of action of CMZ appears not to be limited to GABA A potentiation, 60, 61 since CMZ has been claimed to be a p38-MAPK (mitogen activated protein kinase) pathway inhibitor, although the exact protein target was not defined. 68, 69 In Alzheimer's therapy, inhibition of p38-MAPK is seen as a target, since, for example, Aβ-mediated inhibition of LTP involves stimulation of the p38 MAPK cascade. 62, 63 Compound 4 (Scheme 2) is the lone analogue of CMZ for which mechanistic data have been reported. In the gerbil model of global ischemia, protection by R-4 and S-4 was equivalent to CMZ; 6 however, R-4 was reported to be devoid of anticonvulsant activity, suggested to be compatible with a mechanism involving GABA reuptake inhibition. 7 CMZ has a short half-life and is extensively metabolized. Oxidative metabolism at carbon α to the thiazole ring leads to α-hydroxylation and formation of metabolites from further oxidation, including an α-chloro ketone and aldehyde. 64, 65 The replacement of the secondary α-carbon by addition of a group X (Scheme 1) was justified to prevent metabolic oxidation to potentially electrophilic metabolites. The primary α-hydroxyl metabolite of CMZ was also shown to have sedative activity, providing further reason to limit metabolism at this position. The rationale for exploration of the structural space represented by Z (Scheme 1) using aromatic and heterocyclic groups was based upon the reported biological data on MZ derivative 4 that clearly show central biological actions including neuroprotection. In the absence of an identified CMZ binding site associated with a GABA A subunit, iterative extension of the structural space was carried out by varying the structure and isomerism, represented by n, X, and Z in Scheme 1.
The selection of a bioassay for iterative design and synthesis of MZ derivatives was not immediately apparent. Despite the wealth of reports on CMZ activity in vivo, relatively few publications have described in vitro assays that could be adapted for screening of novel MZ analogues and derivatives for use as neuroprotectants. In SK-N-MC neuroblastoma cells, CMZ was reported to inhibit the glutamate-induced activation of AP-1 mediated by NMDA receptor activation. 66, 67 Immortalized cell cultures (e.g., SK-N-MC and the SH-SY5Y human neuroblastoma cell lines) would provide a facile system for cell-based drug screening; however, in SH-SY5Y cell cultures subject to excitotoxic insults including glutamate, NMDA, and oxygen−glucose deprivation (OGD), CMZ did not produce robust and reproducible neuroprotection (data not shown). Therefore, rat primary cortical neurons were studied as a more complete neuronal model. Excitotoxic cell death from treatment with NMDA (100 μM) was inhibited reproducibly by CMZ treatment and by a number of MZ derivatives and analogues (Supporting Information, Table S1 ).
NMDA excitotoxicity represents only one aspect of neurotoxicity, whereas OGD provides a much more complete model simulating ischemia followed by reperfusion inducing ATP depletion, glutamate release, NMDA receptor overstimulation, mitochondrial dysfunction, ROS generation, apoptosis, and proinflammatory cytokine release. Given the evidence that multiple pathways underlie the anti-inflammatory and neuroprotective activity of CMZ, OGD in primary neurons was seen as the preferred model to screen and to correlate structure of MZ analogues with activity.
The simple 5-ethyl-4-methylthiazole derivatives (22, 23) studied in primary neuron OGD retained neuroprotective efficacy comparable to that of CMZ (Table 1) . In contrast, substitution of the phenyl ring in (4-methylthiazol-5-yl)-(phenyl)methanol derivatives (2 versus 6a and 6b in Table  1 ) significantly reduced efficacy. Further, O-alkylation of 2 led to improved neuroprotection (2 versus 38 and 41 in Scheme 4). Compound 26 (Scheme 3) incorporated a 3-(1H-1,2,3-triazole-4-yl)pyridine pharmacophore within the MZ scaffold. Both 26 and its regioisomer 30 were protective against OGD, whereas replacement of the triazole substitutent in 26 (26 vs 31) or substitution of 3-pyridyl in 5d with 2-pyridyl (5e) led to significant loss of efficacy. The results indicate that both triazole and 3-pyridyl moieties are critical structural elements to the neuroprotective 3-(1H-1,2,3-triazole-4-yl)pyridine fragment.
Mindful of the reports of GABAergic and GABAindependent mechanisms of action for CMZ, the mechanism of neuroprotection of four MZ derivatives was probed using the GABA A receptor channel blocker picrotoxin (100 μM) that has been used extensively for selective antagonism of GABA A mediated signaling. 68−71 Lower concentrations of picrotoxin deliver only partial blockade, 72, 73 and some studies employ higher concentrations. 74, 75 Muscimol, a potent, selective GABA A receptor agonist, was studied for comparison. Instead of OGD, the simpler excitotoxic insult delivered by glutamate (100 μM) was used to induce neuronal loss, measured at 24 h ( Figure 1 ). As anticipated, muscimol produced effective neuroprotection against glutamate toxicity, which was lost and reversed on blockade of the GABA A chloride channel. Neuroprotection produced by 22a mirrored that by muscimol, indicating a GABAergic neuroprotective mechanism. In contrast, neuroprotection by 11c was significantly attenuated by GABA A receptor blockade but was not ablated or reversed, indicating a neuroprotective mechanism only partially dependent on the GABA A receptor. MZ derivatives 26 and 41 demonstrated intermediate neuroprotective mechanisms. On the basis of these collected data, a neuroprotective pharmacophore was speculated ( Figure 1 ). Full elucidation of the individual GABA-dependent and GABA-independent pharmacophores requires extended structure−activity studies; however, the objective was achieved: to develop novel MZ derivatives to be functionalized as NO-chimeras. 3. Synthesis of NO-Chimeras. MZ derivatives (e.g., compounds 5d, 22, 23, and 26, Table 1 ) were selected for further study based upon efficacy for neuroprotection against OGD-induced cell death and the feasibility of structural modification to give nitrate NO-chimeras. Compound 5d is as an excellent neuroprotectant against OGD and NMDA induced cytotoxicity. Compound 16 (Scheme 2) is an analogue of 5d providing a hydroxyl group on the pyridine ring and allowing modification as an NO-chimera. A TMS protected alkyne was introduced into the pyridine derivative 13 via a Sonogoshira reaction, yielding 14, which underwent direct reaction with azide 3 in a basic methanolic solution, as adapted from the literature. 76 The MOM protecting group of 15 was removed, and NO-chimera 18 was prepared by coupling of 16 with 4-nitrooxybutan-1-ol under Mitsunobu conditions. Similarly, 17, the denitration product of 18, was made by using 4-acetyloxybutan-1-ol as reactant followed by deacetylation. Both 16 and 17 are potential metabolites of the NO-chimera 18; notably 16 retained neuroprotective efficacy comparable to that of CMZ (Table 1) .
Two general strategies were used for synthesis of nitrate NOchimeras. The first used simple electrophilic or nucleophilic nitration procedures to generate nitrate esters from alcohol or halide intermediates, respectively. For instance, NO-chimeras 32a,b and 33 were prepared from hydroxyl MZ precursors 22a,b and 23a by the treatment of a mixture of acetic anhydride and fuming nitric acid (Scheme 3). However, this method failed to directly convert 26 to NO-chimera 28; therefore, nitrate 27 was prepared from intermediate 25 and then reacted with 3-ethynylpyridine in the presence of ascorbate and CuSO 4 . The expected instability of the nitrate moiety under these reductive conditions led to a low yield of 26 as major and 28 as minor product. However, a mixture of 25 and alkyne refluxed in toluene successfully gave both regioisomers 28 and 29 by thermal cycloaddition. The nitrate group of 29 was removed using thiol under basic conditions to yield MZ derivative 30 (Scheme 3).
The second strategy of synthesizing NO-chimeras was to incorporate a labile linker group that would distance the nitrate from the MZ core in an approach more akin to that used in hybrid nitrates such as NO-NSAIDs. Esters of cyclopropane carboxylic acid have been reported to possess substantially increased stability toward both acid-and base-catalyzed hydrolysis. 77 Inspired by this observation, 1-nitrooxymethylcyclopropanecarboxylic acid (35, Scheme 4) was prepared by mononitration and sequential oxidation. Acid 35 was coupled with 2 to yield NO-chimera 36 which was expected to have enhanced stability to esterase hydrolysis and therefore theoretically predicted to have enhanced brain bioavailability. An alternative use of this strategy led to design and synthesis of the carbamate prodrug 42, using the isocyanate precursor obtained from 4 reacting with mononitrate 34, again predicted to have further enhanced stability. A similar procedure was used for coupling of 4-nitrooxybutan-1-ol to yield the carbamate 43. Preparation of the amide-linked prodrug 44 and compound 37 Inhibition by picrotoxin of neuroprotection elicited by MZ derivatives in primary neuronal cultures subject to excitotoxic insult. Primary cortical cultures (10−11 DIV) were subjected to 24 h of glutamate (Glut, 100 μM) toxicity with co-treatment of muscimol (Musc) or MZ derivatives (50 μM). Picrotoxin (Picro, 100 μM) was added, where indicated, 1 h before glutamate treatment to provide blockade of GABA A signaling. Survival was measured with the MTT assay and normalized to vehicle treated controls. Data show the mean and SEM from at least six individual experiments analyzed by ANOVA with post hoc Dunnett's MCT compared to nonglutamate treated vehicle control or compared to the efficacy of picrotoxin in blocking each drug treatment effect with a two-tailed t test: * , p < 0.05; * * , p < 0.01; * * * , p < 0.001; ns, not significant. Figure 2 . Representative kinetic traces for hydrolysis of 36 and 37 (10 μM) in phosphate buffer (100 mM, pH 7.4). Incubations were conducted at room temperature and monitored by HPLC with UV detection at 254 nm and fit to a pseudo-first-order rate equation. A putative mechanism is shown for rate acceleration by anchimeric stabilization of the anionic transition state by the nitrate group acting as intramolecular Lewis acid. allowed comparison with the ester-linked prodrug 36. Aliphatic nitrate 40 was synthesized from 2 by O-alkylation with dibromide and subsequent nucleophilic substitution using AgNO 3 . The ethylene glycol linker was incorporated to increase aqueous solubility.
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4. Stability of NO-Chimeras. It was anticipated that future animal studies would require simulation of an extended release formulation, potentially by use of drug in buffered drinking water; therefore, the stability of nitrates was tested in phosphate buffer (100 mM, pH 7.4) using HPLC−UV or LC−MS monitoring. Since the nitrate group itself is stable in acid and mild alkaline solution, the observed stability over 5 days at room temperature of 28, 29, 32a,b, 33, and 40 was expected; the carbamate 43 and amide 44 were also stable. However, to our surprise, hydrolysis of 36 was rapid, rather than being retarded by the hindered α-cyclopropane group, with a half-life of only about 30 min (Figure 2 ). The lability of the nitrooxymethylcyclopropanecarboxylate was unexpected, and therefore, comparison was made with the stability of 37 as an analogue lacking only the nitrate group. The observed half-life of about 380 min for ester hydrolysis confirms that the nitrate group contributes to the instability of 36. We have previously reported the phenomenon of accelerated hydrolysis caused by an adjacent nitrate group ascribed to intramolecular Lewis acid catalysis 78 and propose a similar mechanism for 36 enhanced by a Thorpe−Ingold effect in which the developing negative charge is stabilized by the nitrate moiety through a cyclic transition state ( Figure 2 ). Although more stable than 36, carbamate 42 also decomposed in phosphate buffer with a halflife of approximately 3000 min to yield at least four UVdetectable products that from LC−MS analysis included two denitrated products (m/z = 333) (Supporting Information, Figure S1 ).
Restoration of Synaptic Function by NO-
Chimeras. An early event in AD is synaptic failure leading to deficits in learning and memory. 35 The importance of synaptic alterations in AD has also been confirmed by studies in transgenic mouse models of AD 79 as well as on LTP, a widely studied cellular model of learning and memory. 80 Previous work has reported that synaptic transmission and cognition are altered in double transgenic APP/PS1 mice expressing both the human APP mutation (K670M:N671L) and the human PS1 mutation (M146L). 81, 82 In hippocampal slices obtained from APP/PS1 and WT littermates between 4 and 5 months of age, reproducible LTP responses in the CA1 are observed, with a reduction of LTP in APP/PS1 hippocampal slices, as measured by field excitatory postsynaptic potential (fEPSP). Aβ-induced inhibition of LTP has been observed to be reversed by NOdonors via a mechanism shown to be mediated by the NO/ cGMP signaling pathway. 47 Basal synaptic transmission was determined by measuring the slope of fEPSP at increasing stimulus intensities in slices from 4 to 5 month old APP/PS1 mice for NO-chimeras 32a and 42 (100 μM) perfused for 5 min before inducing LTP through a θ-burst tetanic stimulation of the Schaeffer collateral pathway ( Figure 3 ). 81 Potentiation was observed for 32a, although data for 42 did not reach significance (P < 0.1). The requirement for reductive bioactivation of nitrates to NO and the instability of 42 discussed above are likely causes of the observed differences. The potentiation of the actions of the inhibitory neurotransmitter GABA is not expected to enhance LTP, and accordingly, CMZ did not restore LTP (data not shown).
6. Restoration of Cognition by NO-Chimeras. The stepthrough passive avoidance (STPA) task was used to measure the reversal of a stimulus-response memory deficit induced by the amnesic agent scopolamine that blocks muscarinic acetylcholine receptor activation. Since muscarinic acetylcholine receptor dysfunction is relevant to AD, scopolamineinduced amnesia remains a useful model for screening of drugs for procognitive actions. 83 The STPA task tests learned aversion memory, since mice have a natural preference for dark areas over brightly lit and open areas. Following a period of habituation, the animal is placed in the light compartment of the apparatus and inevitably crosses to the dark compartment of the apparatus, at which time an electric shock is delivered. The animals rapidly learn to avoid moving into the dark compartment during the training phase, despite the administration of the amnesic agent. Retention of this newly learned behavior can be tested on subsequent days to assess the strength of the aversive memory by measuring the latency to enter the dark area. In both training and testing phases, the task is halted after 300 s if the animal does not enter the dark side.
STPA has a significant advantage for drug screening because the potential locomotor effects of drugs are very unlikely to confound the observations. First, all animals must show a uniform learning response to training regardless of drug treatment, which initially entails movement between the compartments until the task is learned. Second, animals are tested 24 and/or 48 h after a single drug treatment, and since most of the drugs, including all NO-chimeras that we have studied to date, have cleared the system long before memory is tested, the STPA task is primarily a measure of memory consolidation.
Scopolamine was administered 30 min and drugs 20 min before training (both ip). Drugs were administered at concentrations equimolar to 1 (1 mg/kg, i.e., 4.45 μmol/kg) to provide comparison to previous work. 84 Administration of scopolamine and vehicle resulted in a latency of less than 100 s for mice to enter the dark side of the apparatus when tested 24 h later, demonstrating an inability to consolidate memory. In contrast, treatment with scopolamine and all novel NOchimeras studied (28, 29, 32a, 32b, 40, 42, 43) significantly restored memory at 24 h (Figure 4 ).
Brain Bioavailability Assessed by LC−MS/MS.
Although the procognitive effects of the NO-chimeras are indicative of brain bioavailability, LC−MS/MS measurements were used to confirm blood−brain barrier penetration. Furthermore, a second objective of these assays was to measure the concentrations of MZ metabolites in the brain after NOchimera delivery, since the neuroprotective properties of the MZ metabolite are an important aspect of the drug design. Figure 5 shows LC−MS/MS chromatograms for multiple reaction monitoring (MRM) after administration of two NOchimeras and their MZ metabolites, representing two subclasses of NO-chimera with different physicochemical properties. The NO-chimera 32a showed good brain bioavailability, and its 5-ethyl-4-methylthiazole metabolite 22a was also observed in the brain of mice 20 min after administration. In contrast, the bioavailability of NO-chimera 28 was low at this time point, whereas the 2-(4-methylthiazol-5-yl)-1H-1,2,3-triazol-1-ylethanol metabolite 26 was readily detected. Calculated parameters suggest that 26 (tPSA = 73 Å 2 ; ClogP < 0) should not penetrate the blood−brain barrier, whereas 22a (tPSA = 33 Å 2 ; ClogP = 1.56) has more favorable properties; however, both MZ derivatives were observed in mouse brains after direct ip administration or after administration of the NO-chimera prodrug. The preliminary replicate analyses after administration of 26 and 28 suggest that the nitrate chimera prodrug elevates brain levels of 26, relative to direct administration of 26 itself (Table 2 ). These data, obtained after ip administration, are predictive of oral bioavailability by comparison with data for 1.
■ CONCLUSIONS
Synaptic failure is an early event in both AD and mild cognitive impairment (MCI), which causes impaired cognition and memory.
1 Disease progression involves neurodegeneration of cortical and hippocampal neurons and loss of hippocampal volume. A drug that targets synaptic failure in addition to providing neuroprotection is a rational approach to AD therapy. Abnormally assembled Aβ and tau proteins are associated with both synaptic and neuronal dysfunction and loss. 3 Aβ has been shown to down-regulate signaling via the NO/cGMP/CREB pathway; therefore, enhancement of NO/ cGMP signaling and activation of CREB may provide a novel approach for the treatment of AD. [39] [40] [41] [42] 47, 85 Gene products associated with CREB activation may provide neuroprotection; however, prevention of neuronal loss can also be achieved by selective pharmacological modulation of GABA A receptors, a mechanism that has been shown to provide neuroprotection against Aβ mediated toxicity.
86−89
Herein, we have elaborated on the concept of an NOchimera, incorporating GABA-mimetic and NO-mimetic mechanisms, by developing and derivatizing novel MZ scaffolds. These chimeric agents represent a novel drug class coined nomethiazoles. The milestones for this study were (1) development of the MZ pharmacophore through synthesis of novel derivatives, (2) assay of neuroprotection in primary neurons, (3) synthesis of nomethiazoles by derivatization of novel, neuroprotective MZ scaffolds, possessing (4) satisfactory stability. Proof-of-concept for nomethiazoles was achieved by demonstration of (5) synaptic rescue using LTP measurements ex vivo, (6) restoration of learning and memory in vivo, and (7) brain bioavailability of both NO-chimeras and their MZ metabolites. It was confirmed that 1 is a prototype of a novel drug class that possesses a combination of GABA-mimetic and NO-mimetic activities, thus providing both neuroprotection and neurorestoration. Since neurodegenerative diseases such as AD are multifactorial, the development of drugs designed to target more than one mechanism of action is likely to be a promising therapeutic approach.
■ EXPERIMENTAL SECTION Synthesis.
1 H and 13 C NMR spectra were obtained with Bruker Ultrashield 400 MHz and Advance 300 MHz spectrometers. Chemical shifts are reported as δ values in parts per million (ppm) relative to tetramethylsilane (TMS) for all recorded NMR spectra. All reagents and solvents were obtained commercially from Acros, Aldrich, and Fluka and were used without purification. Low-resolution mass spectrometry (LRMS) was conducted on an Agilent 6300 ion-trap LC−MS instrument. High resolution mass spectral data were collected using a Shimadzu QTOF 6500 instrument. All compounds submitted for biological testing were found to be >95% pure by analytical HPLC. Purity and/or low resolution mass spectral (ESI or APCI) analysis was measured using an Agilent Zorbax Bonus C18, 3.5 μm, 150 mm × 3.0 mm column on either a Shimadzu UFLC or Agilent 1100 series HPLC instrument in tandem with an Agilent 6310 ion trap LC−MS instrument. HPLC parameters were the following: 0.1% FA in 10% CH 3 OH (solvent A); 0.1% FA in CH 3 CN (solvent B); flow rate 0.5 mL/min; gradient, t = 0 min, 10% A; t = 1 min, 10% A; t = 18 min, 80% A; t = 20 min, 80% A; t = 21 min, 95% A.
1-(4-Methyl-5-thiazolyl)-1-phenylmethanol (2). 4-Methyl-5-thiazolecarboxaldehyde (1.0 g, 7.8 mmol) was dissolved in THF (40 mL) and cooled in an ice bath, and phenylmagnesium bromide (1 M in THF, 8.5 mL) was added dropwise. The reaction mixture was warmed to room temperature and stirred overnight. The reaction was quenched with aqueous NH 4 Cl, and extraction was with ethyl acetate (2 × 100 mL). Organic solutions were combined and concentrated, and the crude product was purified by column chromatography (hexanes/ethyl acetate, 1:1, 1.4 g, 87% 
5-(Azidophenylmethyl)-4-methylthiazole (3)
. MsCl (2.9 mL) was added to a solution of 2 (6.2 g) and NEt 3 (6.0 mL) in anhydrous acetonitrile (70 mL). Reaction was monitored by TLC until the starting material was consumed. NaN 3 (6.1 g) was added, and the mixture was stirred at room temperature overnight. Most of the acetonitrile was removed under reduced pressure. The residue was diluted with ethyl acetate and washed with water. The organic phase was separated and concentrated, and the crude product was purified by column chromatography (hexane/ethyl acetate, 2:1, 75% (4) . LiAlH 4 (130 mg, 3.5 mmol) was added to a solution of 3 (320 mg, 1.39 mmol) in anhydrous THF (10 mL). The mixture was refluxed for 1 h and quenched with 0.1 N NaOH. The residue was diluted with water and extracted using ethyl acetate (2 × 25 mL). Organic solutions were combined and concentrated, and the crude product was purified by column chromatography (DCM/MeOH, 15:1, 230 mg, 82%).
13 C Figure 5 . MRM LC−MS/MS chromatograms of extracted mouse brain samples 20 min after ip delivery of each drug at a dosage that was equimolar with 1 (4.5 μmol/kg): (A) 26 with 8 used as internal standard; (B) 28 with 8 used as internal standard; (C) 22a with 22b used as internal standard; (D) 32a with 22b used as internal standard. 5-(2-Azidoethyl)-4-methylthiazole (10). MsCl (2.1 g, 18.1 mmol) was added to a solution of 9 and DIPEA (3.7 mL, 22.3 mmol) in anhydrous acetonitrile (100 mL). Reaction was monitored by TLC until the starting material was consumed. NaN 3 (2.7 g, 41.9 mmol) was added, and the mixture was refluxed for 3 h. Most of the acetonitrile was removed under reduced pressure. The residue was diluted with ethyl acetate and washed with water. The organic phase was separated and concentrated, and the crude product was purified by column chromatography. Product was obtained as a slightly yellow oil. 1 (13) . 3-Bromo-5-hydroxypyridine (1.0 g, 5.7 mmol) and MOM-Br (0.64 mL, 6.9 mmol) were dissolved in THF(10 mL). Anhydrous K 2 CO 3 (1.5 g, 10.9 mmol) was added, and the reaction mixture was stirred overnight. After filtration and concentration, the product was purified by column chromatography (SiO 2 , hexane/ethyl acetate, 3:1, 1.1 g, 88%) . 1 2 Cl 2 (162 mg, 0.23 mmol) were placed in a flask and filled with argon. THF (10 mL) was added using a syringe followed by NEt 3 (3.0 mL, 21 mmol) and ethynyltrimethylsilane (0.7 mL, 5.1 mmol). The reaction mixture was stirred overnight at room temperature. Most of the solvent was removed, and the residue was purified by column chromatography (SiO 2 , hexane/ethyl acetate, 5:1, 0.85 g, 81% (15) . Azide 3 (783 mg, 3.4 mmol) and alkyne 14 (0.8 g, 3.4 mmol) were dissolved in a mixture of MeOH and water (2:1, 5 mL). K 2 CO 3 (484 mg, 3.5 mmol), CuSO 4 ·5H 2 O (170 mg, 0.68 mmol), and sodium ascorbate (272 mg, 0.68 mmol) were added, and the reaction mixture was stirred at room temperature overnight. Most of the solvent was removed under reduced pressure. The residue was dissolved in DCM and washed with water. The organic phase was separated and concentrated, and the crude product was purified by column chromatography (DCM/ MeOH, 20:1, 1.15 g, 86%). 1 ) were dissolved in THF (5 mL), and the flask was filled with argon. The solution was cooled in an ice bath, and DIAD (230 μL, 1.1 mmol) was added using a syringe. The mixture was stirred overnight and quenched with water. After workup, the crude product was dissolved in methanol (10 mL) and treated with K 2 CO 3 (140 mg). ( 37 mg, 0.14 mmol) were dissolved in THF (2 mL), and the flask was filled with argon. The solution was cooled in an ice bath, and DIAD (40 μL) was added using a syringe. The mixture was stirred overnight and quenched with water. Solvent was removed, and crude product was purified by purified by column chromatography (DCM/MeOH, 20:1, 67% (20) . 4-Methyl-5-vinylthiazole (900 mg, 7.2 mmol) was dissolved in a mixture of dioxane (2.5 mL), H 2 O (5 mL) and acetic acid (430 mg). NBS (1.4 g, 7.9 mmol) was added in three portions. The reaction mixture was stirred at room temperature for 1 h and then diluted with ethyl acetate (50 mL). The organic phase was separated and concentrated, and the product was purified by column chromatography (SiO 2 , hexane/ethyl acetate, 1.5:1, 900 mg, 52%). 4-Methyl-5-(2-oxiranyl)thiazole (21) . Bromohydrin 20 (650 mg, 2.94 mmol) was dissolved in MeOH (10 mL). K 2 CO 3 (1.2 g, 8.8 mmol) was added, and the reaction mixture was stirred at room temperature for 1 h. Solvent was removed under reduced pressure, and the residue was diluted with hexane and ethyl acetate (50 mL, 2:1 v/ v). After filtration and concentration, the product was obtained with enough purity for the next step reaction. 1 β-Phenyl-4-methyl-5-thiazoleethanol (22a) and α-(Phenylmethyl)-4-methyl-5-thiazolemethanol (23a). Crude epoxide 21 (1.0 g, 7.1 mmol) was dissolved in anhydrous THF (10 mL) and added dropwise to a phenylmagnisum bromide solution (1 M in THF, 10 mL) at 4°C. The reaction mixture was stirred overnight at room temperature, quenched with aqueous NH 4 Cl, and extracted with ethyl acetate (2 × 50 mL). The organic phase was separated and concentrated. 22a and 23a were separated and purified by column chromatography (SiO 2 , hexane/ethyl acetate 1:1). 22a (major product, 1.0 g, 65%), 1 22b and 23b were synthesized using the procedure described above for 22a from epoxide 21 and 4-fluorophenylmagnisum bromide. Products were separated and purified by column chromatography (SiO 2 , hexane/ethyl acetate, 1:1). 22b (major product, 60%), 1 (24) . Caboline (500 mg, 2.5 mmol) was dissolved in DMSO (5 mL). NaH (120 mg, 60%, 3 mmol) was added, and the mixture was stirred for 5 min. 4-Methyl-5-vinylthiazole (2.86 mL, 25 mmol) was added, and the reaction mixture was heated at 90°C for 5 h. Reaction was quenched with MeOH (0.5 mL), and the solvent was evaporated under high vacuum. The residue was dissolved in DCM (20 mL) and washed with water. The organic phase was separated and concentrated, and the product was purified by column chromatography (SiO 2 β-Azido-4-methyl-5-thiazoleethanol (25) . Epoxide 21 (400 mg, 2.8 mmol) was dissolved in acetonitrile and water (1:1, 10 mL). NaN 3 (553 mg, 8.4 mmol) was added. The reaction mixture was refluxed for 1 h. Most of the solvent was removed under reduced pressure. The residue was dissolved in DCM (20 mL) and washed with water. The organic phase was separated and concentrated, and the crude product was purified by column chromatography (SiO 2 , hexane/ethyl acetate, 1:1, 410 mg, 61% 1-Nitrooxy-β-azido-(4-methyl-5-thiazoyl)ethane (27) . 25 (400 mg, 2.17 mmol) was dissolved in DCM (10 mL) and cooled in an ice bath. Fuming nitric acid (130 μL) and acetic anhydride (245 μL) were added. The reaction mixture was stirred at 0−4°C for 4 h. After dilution with ethyl acetate (20 mL), the reaction mixture was neutralized by saturated aqueous NaHCO 3 . The organic phase was separated and concentrated, and the crude product was purified by column chromatography (SiO 2 , hexane/ethyl acetate, 2.5:1, 350 mg, 71%). 1 13 (m, 1H), 2.56 (s, 3H) . 13 (31) . 22c (350 mg, 1.4 mmol), 3-pyridineboronic acid (270 mg, 2.2 mmol), Pd(OAc) 2 (15 mg), (2-biphenyl)di-tert-butylphosphine (41 mg), and KF (240 mg, 4.1 mmol) were placed in a flask filled with argon. DMF (10 mL) was added using a syringe. The mixture was heated at 120°C for 1 h. DMF was removed under vacuum, and the residue was diluted with DCM (50 mL) and washed with water. The crude product was purified with column chromatography (DCM/MeOH, 20:1, 58%). β-Phenyl-(4-methyl-5-thiazolyl)ethane-1-nitrate (32a). 22a (150 mg, 0.68 mmol) was dissolved in DCM (3 mL) and cooled in an ice bath. Fuming nitric acid (120 μL) and acetic anhydride (280 μL) were added. The reaction mixture was stirred at 0−4°C for 4 h. After dilution with ethyl acetate (20 mL), the reaction mixture was neutralized by saturated aqueous NaHCO 3 . The organic phase was separated and concentrated, and the crude product was purified by column chromatography (SiO 2 , hexane/ethyl acetate, 3:1, 110 mg, 61% (34) . 1,1-Bis-(hydroxymethyl)cyclopropane (5.0 g, 48.9 mmol) was dissolved in DCM (100 mL) and cooled in an ice bath. Fuming nitric acid (2.5 mL) followed by acetic anhydride (5 mL) was added slowly. The mixture was stirred at 4°C for 4 h and quenched by aqueous NaHCO 3 . The organic phase was separated and washed with water. The crude product was purified by column chromatography (hexanes/ ethyl acetate, 4:1, 1.2 g, 17% (35) . Compound 34 (1.9 g, 12.9 mmol) was dissolved in DCM (100 mL). TEMPO (0.4 g, 2.6 mmol) and PhI(OAc) 2 (4.5 g, 14.2 mmol) were added successively. The reaction mixture was stirred until the alcohol was no longer detectable by TLC. The reaction mixture was washed with aqueous Na 2 S 2 O 3 , NaHCO 3 , and H 2 O. The organic phase was separated and concentrated. The residue was purified by column chromatography (hexanes/ethyl acetate, 2:1). The starting material was oxidized to an aldehyde as a white solid (1.3 g, 70%) . 1 g, 7. 6 mmol) and 2-methyl-2-butene (8.8 mL) were dissolved in t-BuOH (50 mL). NaH 2 PO 4 ·H 2 O (10.0 g) and NaClO 2 (9.0 g) were mixed with H 2 O (25 mL), and then the mixture was added to the t-BuOH solution. The reaction mixture was stirred overnight. Solvent was removed under reduced pressure, and the residue was diluted with ethyl acetate (200 mL) and washed with aqueous Na 2 S 2 O 3 (25 mL), NaHCO 3 (25 mL), and H 2 O (2 × 40 mL). The organic phase was separated, dried over anhydrous MgSO 4 , and concentrated. Product was obtained as a white solid (1.1 g, 90%) . 1 (38) . To a solution of 2 (200 mg, 0.87 mmol) in DMF (4 mL) was added NaH (52 mg, 60%, 0.87 mmol). The reaction mixture was stirred at room temperature for 15 min. CH 3 I (65 μL, 1 mmol) was added, and the reaction mixture was stirred for another 3 h. The reaction was quenched with MeOH (1 mL), and then most of the solvent was removed under vacuum. The residue was dissolved in ethyl acetate (50 mL) and washed with water. The organic phase was separated and concentrated. The crude product was purified by column chromatography (SiO 2 , hexane/ethyl acetate, 2:1, 150 mg, 70% (39) . To a solution of 2 (500 mg, 2.4 mmol) in DMF (5 mL) was added NaH (117 mg, 2.92 mmol). The reaction mixture was stirred at room temperature for 15 min. Bis(2-bromomethyl) ether (2.2 g, 9.6 mmol) was added, and the reaction mixture was stirred for another 3 h. The reaction was quenched with MeOH (1 mL), and then most of the solvent was removed. The residue was dissolved in ethyl acetate (50 mL) and washed with water. The organic phase was separated and concentrated. The crude product was purified by column chromatography (SiO 2 , hexane/ethyl acetate, 2:1, 740 mg, 86% (40) . Silver nitrate (2.0 g, 11.8 mmol) was added to a solution of 39 (1.1 g, 3.1 mmol) in CH 3 CN (15 mL). The reaction was refluxed for 2 h and then diluted with ethyl acetate (50 mL). After filtration and concentration, the crude product was purified by column chromatography (SiO 2 , hexane/ethyl acetate, 1.5:1, 720 mg, 69% (42) . Compound 4 (160 mg, 0.78 mmol) and triphosgene (297 mg, 1.0 mmol) were dissolved in ethyl acetate (10 mL) and refluxed for 2 h. Solvent was removed. The residue was redissolved in a mixture of THF (5 mL) and NEt 3 (0.25 mL, 1.8 mmol), and 34 (147 mg, 1 mmol) was added. The reaction mixture was stirred at 40°C for 1 h. Solvent was removed, and the product was purified by column chromatography (SiO 2 , hexane/ethyl acetate, 2:1, 150 mg, 51% and 5i (internal standard, 10 μM) were dissolved in phosphate buffer (100 mM, pH 7.4), and the final concentration of DMSO was 2% (v/ v). The solution was kept in the autosampler of the HPLC instrument at room temperature, and an aliquot (50 μL) was injected into HPLC column. Injection occurred about every 7 min for 36 and 67 min for 37 because of the different stability of the two compounds. HPLC analysis was performed using a Shimadzu UFLC instrument with UV absorbance detection at 254 nm. Separation of parent compound, hydrolysis product (compound 2), and internal standard (IS) was achieved using a Hypersil BDS C18 column (2.1 mm × 30 mm, 3 μm). The composition of the HPLC mobile phase was a mixture of water with 10% methanol, 0.1% formic acid (solution A), and acetonitrile with 0.1% formic acid (solution B). The mobile phase was initially composed of solvent A/solvent B (90:10), held for 1 min, and then a linear gradient of solution B from 10% to 95% over the next 3 min. The solvent was held at 95% of solution B over 1 min, and the column was finally balanced using 10% solvent B for 1.5 min. Flow rate was 0.5 mL/min. Peak area ratio of parent compound vs internal standard was calculated at each time point and divided by the time zero value to give the percentage of compound remaining.
3-(Methoxymethoxy)-5-[1-[(4-methyl-5-thiazolyl)-phenylmethyl]-1H-1,2,3-triazol-4-yl]pyridine
To detect the decomposition products of 42, the compound (100 μM) was dissolved in phosphate buffer (100 mM, pH 7.4). The final concentration of DMSO was 2% (v/v). The sample was placed in the dark at room temperature for 48 h. An aliquot (10 μL) of the sample was analyzed using an Agilent 6310 ion trap mass spectrometer (Agilent Technologies, Santa Clara, CA) equipped with Agilent 1100 HPLC system and electrospray ionization (ESI) source operated in positive mode. HPLC was performed using an Agilent Zorbax Bonus reverse phase C18 column (3.0 mm × 150 mm, 3.5 μm) with UV absorbance detection at 254 nm. The composition of the HPLC mobile phase was a mixture of water with 10% methanol, 0.1% formic acid (solution A), and acetonitrile with 0.1% formic acid (solution B). The mobile phase was initially composed of solvent A/solvent B (90:10), held for 1 min, and then a linear gradient of solution B from 10% to 80% over 17 min, 0.5 min gradient of solution B from 80% to 95% and held for 5 min. Flow rate was set at 0.5 mL/min.
Animals. Male C57BL/6 mice aged 8−10 weeks (20−25 g, Charles River Laboratories, IL) were used for step-through passive avoidance (STPA) task and brain bioavailability assay. Sprague−Dawley rat (gestational days 17−18, Charles River Laboratories, IL) were used for the primary neuronal cultures. Animals were housed at the BRL (biological resources laboratories) animal facility at the University of Illinois at Chicago (UIC). The animals were kept under standard laboratory conditions with free access to dry food and water but no nesting materials (Nestlets) supplied (not enriched environment). Regular light−dark cycle with at least 12 h of light was maintained throughout the housing in the facility. Animals were acclimated for at least 1 week in BRL before running any experiment. Also, 1−2 h prior to each testing, mice were habituated to the animal study room in the facility. All protocols using live animals were reviewed and approved by Institutional Animal Care and Use Committee (IACUC) at UIC (Animal Care Committee). Injection volumes were adjusted based on the animal weight (0.1 mL/25 g mouse).
Double transgenic APP/PS1 mice expressing both the human APP (K670M:N671L) and PS1 (M146L) (line 6.2) mutations were used for the LTP study. They were obtained by crossing APP with PS1 animals. 38 The animals were maintained on a 12 h light/dark cycle (with light onset at 6:00 a.m.) in temperature-and humidity-controlled rooms of the Columbia University Animal Facility. Food and water were available ad libitum.
Primary Neuronal Cultures. Primary cultures of rat cortical neurons were prepared as described. 91 Briefly, brains were removed from embryonic day 17 Sprague−Dawley rat embryos, cortices were dissected, and meninges were removed. Neurons were mechanically dissociated in basal medium Eagle 1× containing glucose (33 mM), glutamine (2 mM), 10% horse serum, and 10% FBS and then plated at 3 × 10 5 cells/cm 2 in poly-L-lysine-precoated plates. The medium was replaced 24 h later with serum-free neurobasal medium (NBM) supplemented with 0.5 mmol/L-glutamine and 2% complete B27 supplement. Four days later, 50% of the medium was replaced with fresh NBM. Neurons were used for OGD or NMDA cytotoxicity experiments after being grown for 8−10 days in NBM.
Primary Neurons Subject to Transient OGD Followed by Reoxygenation. Primary cortical cultured neurons were subjected to a transient OGD as described. 92 On days 8−10 of culture, cultured neurons were placed in a humidified 37°C incubator (95% N 2 , 5% CO 2 ) and the culture medium was replaced with deoxygenated, glucose-free balanced salt solution, pH 7.4, containing the following (in mM): NaCl 116, CaCl 2 1.8, MgSO 4 0.8, KCl 5.4, NaH 2 PO 4 1, NaHCO 3 14.7, and HEPES 10. Following 2 h of OGD incubation, OGD was ended by replacing OGD medium with testing compound conditioned fresh NBM (supplemented with 0.5 mmol/L-glutamine and B27 without antioxidants). Cultures were returned to the normoxic 37°C incubator (5% CO 2 ) for 24 h prior to evaluation of cell viability and neuronal death by MTT and LDH assays. The test compounds (50 μM) were present during the 2 h OGD and 24 h reoxygenation.
NMDA and Glutamate Induced Cytotoxicity in Primary Neurons. Primary cortical cultured neurons were subjected to NMDA induced cytotoxicity as described. 93, 94 On day 11 of culture, primary neurons were preincubated with testing compounds (50 μM) for 30 min in neurobasal culture mudium and were exposed to NMDA (100 μM) in HEPES-buffered salt solution containing the following (in mM): NaCl 20, KCl 5.4, MgCl 2 0.8, CaCl 2 1.8, glucose 15, and HEPES 20 (pH 7.4). Twenty-four hours later, cell viability and neuronal death were evaluated by MTT and LDH assays. The testing compounds (50 μM) were presented during the preincubation and 24 h chronic NMDA cytotoxicity. MTT assay for cell viability and LDH assay of cell death were performed as described previously. 95 To probe the mechanism of neuroprotection elicited by MZ derivatives, after 10−11 DIV (days in vitro), picrotoxin (100 μM) was added to primary neuronal cultures 1 h before glutamate (100 μM) insult. One hour after glutamate addition, MZ derivatives or muscimol were supplied at a final concentration of 50 μM. After incubation for 24 h, final cell survival was assayed using MTT. For comparison, picrotoxin treatment was omitted in another experiment.
LTP Measurement. Hippocampal slice preparation was performed as described. 38 Briefly, APP/PS1 trangenic mice were decapitated and their hippocampi were quickly removed. Transverse hippocampal slices (400 μm) were cut and transferred to an interface chamber, where they were maintained at 29°C. They were perfused (1−3 mL/ min) with saline solution (124.0 mM NaCl/4.4 mM KCl/1.0 mM Na 2 HPO 4 /25.0 mM NaHCO 3 /2.0 mM CaCl 2 /2.0 mM MgSO 4 /10 mM glucose) continuously bubbled with 95% O 2 and 5% CO 2 . Slices were maintained at 29°C for 90 min before recording. The CA1 region of the hippocampus field excitatory postsynaptic potentials (fEPSPs) were recorded by placing both the stimulating and the recording electrodes in CA1 stratum radiatum. A 15 min baseline was recorded every minute at an intensity that evokes a response of approximately 35% of the maximum evoked response. LTP was induced using θ-burst stimulation at 20 min. Responses were recorded for 1 h after tetanization.
Step-Through Passive Avoidance (STPA) Task. The STPA apparatus consists of a two-compartment acrylic box with an illuminated side (15 cm × 12 cm × 12 cm) connected to a dark side (15 cm × 12 cm × 12 cm) by a vertical door. The dark side is equipped with an electric grid floor. Animals was habituated to translocating to the dark from the light side until latency of entering the dark side for each animal is <30 s. During training, animals received an aversive electrical shock (0.5 mA, 2 s), triggered by entry to the dark compartment, until the latency of entering the dark side reaches 300 s. To test procognitive activity of NO-chimeras, scopolamine (1.0 mg/kg, ip) was given 30 min before training and drug (4.5 μmol/kg, ip) was administered 20 min before training. At 24 h after training, the animals were again individually placed in the light compartment and the latency to enter the dark comparment, without shock stimulus, was recorded. Statistical analysis of the latency data was performed with one-way ANOVA followed by Bonferroni multiple comparison test.
Brain Bioavailability of NO-Chimeras. Mice were injected (ip) with drug at a dosage that was equimolar with 1 (4.5 μmol/kg, ip). Four mice were used for the injection of each drug. Brain tissues were collected 20 min after ip injection. Analytes were extracted as follows: to a mixture of blank brain tissue (100 mg) and cold acetonitrile/ MeOH (1:1, 600 μL), internal standard (400 ng/mL, 10 μL) in acetonitrile/MeOH (1:1) was added. Brain tissue was homogenized manually using a disposable pestle, vortexed, and then centrifuged at 4°C , 13 000 rpm for 15 min. The supernatant was transferred to another vial. The remaining pellet was washed and extracted with cold acetonitrile/MeOH (300 μL,1:1 v/v) and centrifuged as described above. Supernatants were combined and stored at −20°C for 1 h, allowing further protein precipitation. The clear supernatant from centrifugation was collected and concentrated using a flow of N 2 . The residue was reconstituted with solvent (200 μL, H 2 O/MeOH/ acetonitrile, 50/25/25, v/v), vortexed, centrifuged, and analyzed using LC−MS/MS. To construct standard curves, working solutions in MeOH/acetonitrile/H 2 O (0.5:0.5:1) containing NO-chimera and corresponding hydroxyl compound at different concentrations were prepared. Concentrations of working solutions were 2000, 1000, 500, 200, 80, 40, 20 ng/mL. To a mixture of blank brain tissue (100 mg) and cold acetonitrile/MeOH (1:1, 600 μL) were added each analyte working solution (10 μL) and internal standard (400 ng/mL, 10 μL). Calibration samples were extracted as described above, and the final concentrations of analytes after reconstitution were 100, 50, 25, 10, 4, 2, 1 ng/mL. The final concentration of IS was 20 ng/mL.
All LC−MS/MS measurements were carried out using the positive mode electrospray ionization method on an API 3000 (Applied Biosystem, Foster City, CA) triple quadrupole mass spectrometer attached to an Agilent 1200 HPLC (Agilent Technologies) instrument. MRM transitions for the detection of analytes and internal standards are described in Table 2 . HPLC was performed with a Waters XBridge C18 column (3.5 μm, 3 mm × 100 mm). Flow rate was set at 0.35 mL/min. The composition of the HPLC mobile phase was a mixture of water with 10% methanol, 0.1% formic acid (solution A), and acetonitrile with 0.1% formic acid (solution B). To analyze 32a and 22a, the mobile phase was initially composed of solvent A/ solvent B (90:10), held for 1 min, and a linear gradient of solution B from 10% to 60% over the next 1 min. The composition of B was then increased to 99% in 13 min. The solvent was held at 99% of solution B over 5 min, and the column was finally balanced using 10% solvent B for 5 min. To analyze 26 and 28, the mobile phase was initially composed of solvent A/solvent B (95:5), held for 1 min, and a linear gradient of solution B from 10% to 60% over next 1 min. Composition of B was then increased to 99% in 11 min. The solvent was held at 99% of solution B over 5 min, and the column was finally balanced using 5% solvent B for 5 min.
Statistical Analyses. For all experiments, data were expressed as the mean ± SEM. LTP results were analyzed with two-way ANOVA. STPA results were analyzed with one-way ANOVA followed by Bonferroni multiple comparison test. The level of significance was set for p < 0.05.
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